CALT News and Press, Calliditas Therapeutics AB From 03/31/23

Calliditas to participate in upcoming investor conferences PR Newswire STOCKHOLM , March 31, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced its management's participation in the following i...

2023-03-13 13:15:19 ET Calliditas Therapeutics ( NASDAQ: CALT ) added 35% on Monday after announcing that its Phase 3 trial for renal disease candidate Nefecon reached the primary endpoint, paving the way for Swedish pharma to seek its full approval. In Dec. 2021, the U....

2023-03-13 12:54:16 ET Gainers: Provention ( PRVB ) +258% . Euda Health ( EUDA ) +41% . Calliditas ( CALT ) +31% . Cipher Mining ( CIFR ) +29% . Caleminder ( CMND ) +26% . Bakkt ( BKKT ) +26% . Hut 8 Mining ( HU...

2023-03-13 10:02:38 ET Gainers: Provention Bio PRVB +248% . Caleminder ( CMND ) +38% . Calliditas Therapeutics ( CALT ) +32% . Euda Health ( EUDA ) +22% . Seagen  ( SGEN ) +15% . Losers: Cingulate CING -28...

2023-03-13 08:54:26 ET Provention Bio PRVB +263% on ~$2.9B acquisition by Sanofi. Calliditas Therapeutics ( CALT ) +29% announces primary endpoint successfully Met in phase 3 NefIgArd trial evaluating Nefecon® in IgA Nephropathy. Caleminder ( CMND ...

Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA Nephropathy PR Newswire STOCKHOLM , March 13, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Callidi...

Summary Calliditas Therapeutics is a commercial-stage biopharmaceutical company based in Sweden focused on developing and commercializing novel treatments for rare diseases. TARPEYO is the only disease-modifying therapy approved for IgAN. We expect TARPEYO's 2023 sales to be better ...

Calliditas Therapeutics press release ( NASDAQ: CALT ): Q4 GAAP loss of -SEK0.07 Revenue of SEK429M vs. SEK31.2M in 4Q21. For further details see: Calliditas Therapeutics reports Q4 results

Calliditas - Year-End Report, 2022 PR Newswire 2022: Successful transformation into a commercial stage company STOCKHOLM , Feb. 23, 2023 /PRNewswire/ -- "2022 was a fantastic year for Calliditas as we launched TARPEYO ® in the US, the first a...

Summary Sparsentan is approved for IgAN with a disappointing FDA label. We believe the approval is fully priced in, and we expect disappointing sales print during the first few years and fierce competition with Chinook's Atrasentan later on. Sparsentan is expected to launch in Feb 2...